

# Laercio Lopes Da Silva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623941/publications.pdf>

Version: 2024-02-01

17  
papers

181  
citations

1307594

7  
h-index

1199594

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

232  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance therapy following an anti-EGFR-based induction regimen in metastatic colorectal cancer (mCRC): A network meta-analysis of clinical trials.. Journal of Clinical Oncology, 2022, 40, 128-128.	1.6	2
2	Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors.. Journal of Clinical Oncology, 2022, 40, e17615-e17615.	1.6	0
3	Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clinical and Translational Oncology, 2021, 23, 100-109.	2.4	30
4	Comparison of systemic therapy efficacy in advanced hepatocellular carcinoma: Systematic review and frequentist network meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2021, 39, 293-293.	1.6	1
5	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 145-154.	3.7	12
6	Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers, 2021, 13, 1715.	3.7	19
7	Efficacy and safety of PD-1 inhibitors as first- and second- line treatments for advanced gastroesophageal cancers: A network meta-analysis of phase III clinical trials.. Journal of Clinical Oncology, 2021, 39, e16032-e16032.	1.6	0
8	Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. Cancers, 2021, 13, 2614.	3.7	11
9	Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO Oncology Practice, 2021, 17, e629-e636.	2.9	13
10	Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 3557-3557.	1.6	4
11	The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncology, 2021, 17, 4221-4231.	2.4	4
12	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy, 2020, 12, 1183-1193.	2.0	12
13	The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries. Nature Cancer, 2020, 1, 1140-1152.	13.2	33
14	Association Between the Functional miR-146a SNP rs2910164 and Risk of Digestive System Cancer: Updated Meta-analysis. Anticancer Research, 2020, 40, 1495-1502.	1.1	4
15	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 258.	2.8	35
16	Checkpoint inhibitor-associated immune-related adverse events as harbinger of favorable clinical outcome: Systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, e15129-e15129.	1.6	0
17	Treatment-related adverse events of combination immune checkpoint inhibitors: Systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, e15060-e15060.	1.6	1